BSE: 544143
Royal Sense Limited
Develops and sells branded pharmaceutical formulations for the Indian domestic market, with products across antibiotics (Stergiclav 625 and Smartyclav 625), CNS and psychiatric medications (Sterprax and Stergipam MD), pain management (Stergicet with paracetamol and tramadol), sleep aids (Sterpidem MD with zolpidem), and home healthcare devices including a digital blood pressure monitor. Royal Sense Limited sells all pharmaceutical products as prescription-only medicines under Schedule H classification. Through its wholly-owned subsidiary Stergic Retail Private Limited, the company entered pharmacy retail on 23 February 2026 with the first Stergic Pharmacy counter at Deep Vihar, Rohini Sector-22, Delhi. Consolidated FY26 revenue from operations stood at Rs 103.3759 crore, up 67.4% YoY, while standalone revenue grew 36.7% to Rs 3,778.57 lakhs. The subsidiary contributed Rs 416.76 lakhs to consolidated profit after tax of Rs 657.20 lakhs. Employee costs at 3.7% of revenue and other operating expenses at 4.6% are the disclosed cost lines. A new warehouse in Sonipat was taken on a five-year lease from 1 February 2026 to support distribution. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Branded pharmaceutical formulations, Pharmacy retail. Pharmaceutical formulations business with early-stage pharmacy retail expansion, BSE SME-listed
Exhibit 1: Financial summary, FY24–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 18 | 62 | 103 |
| EBITDA (ex other income) | — | — | — |
| margin % | — | — | — |
| Owners' profit | — | — | — |
| EPS, as reported (₹) | 3.24 | 12.91 | 13.46 |
| ROE % · ROCE % | — · 12.4 | — · 32.1 | — · 26.1 |
| Debt / equity (x) | — | — | — |
| Cash from operations | (4) | 1 | (13) |
| Capex | — | (2) | 0 |
Exhibit 2: Quarterly performance, last 5 quarters
| ₹ crore | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 22 | 40 | 43 | 60 |
| Profit before tax | 0 | 3 | 6 | 5 | 5 |
| Net profit | — | — | — | — | — |
| EPS (₹) | 0.00 | 4.85 | 8.07 | 7.63 | 5.83 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 14,930 | 47.4 | 4.74 | 27.4 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 1,651 | 10.5 | 4.29 | 30.9 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,593 | 143.3 | 2.51 | 13.8 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 996 | 32.0 | 4.08 | 21.4 | 11.8 | 11.0 | — | 22.3 |
| Hemant Surgical Industries Lim | 743 | 28.4 | — | — | — | 16.7 | — | — |
| FABTECH TECHNOLOGIES LTD | 566 | 9.2 | 1.35 | 9.1 | 9.1 | 10.7 | — | 9.9 |
| Prevest Denpro Limited | 455 | 15.4 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 296 | 60.7 | 1.64 | 35.6 | 1.2 | 2.7 | (7.2) | 13.0 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 2.6 | 21.0 | 1 of 16 | 100% |
| ROCE | 23.6 | 11.3 | 1 of 17 | 100% |
| Market cap | 37 | 164 | 14 of 17 | 19% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 26 Oct 2026 · Promoter releases pledge over 10 lakh Royal Sense shares | ownership changes | high | — | — |
| 5 Oct 2026 · Royal Sense Limited - Compliance Certificate under Reg 74(5) SEBI DP Regs for H1 FY27 | compliance | minimal | — | — |
| 5 Oct 2026 · Royal Sense appoints internal and secretarial auditors for FY26-27 | management changes | medium | — | — |
| 29 Sept 2026 · AGM results: all 7 resolutions passed with 100% approval | compliance | minimal | — | — |
| 28 Sept 2026 · Royal Sense 3rd AGM: ESOP plan, capital hike, MD re-appointment transacted | board shareholder meetings | low | — | — |
| 25 Sept 2026 · Trading window closed from Oct 1, 2026 till H2 results announcement | compliance | minimal | — | — |
| 21 Sept 2026 · Promoter Rishabh Arora releases pledge on 10 lakh shares | ownership changes | high | — | — |
| 21 Sept 2026 · Royal Sense: Promoter Rishabh Arora releases pledge on 10 lakh shares | ownership changes | medium | — | — |
| 5 Sept 2026 · Royal Sense 3rd AGM on Sep 28; book closure Sep 21-27 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Royal Sense files FY26 Annual Report; standalone revenue up 37%, PAT flat | results | high | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.